


## Ibuzatrelvir

<b>Cat. No.:</b>	HY-156654
<b>CAS No.:</b>	2755812-39-4
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>30</sub> F <sub>3</sub> N <sub>5</sub> O <sub>5</sub>
<b>Molecular Weight:</b>	489.49
<b>Target:</b>	SARS-CoV; Virus Protease
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (204.29 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	2.0429 mL	10.2147 mL	20.4294 mL
		5 mM	0.4086 mL	2.0429 mL	4.0859 mL
10 mM	0.2043 mL	1.0215 mL	2.0429 mL		
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Ibuzatrelvir (PF-07817883) is an antiviral agent, targeting to SARS-CoV-2 3CL protease. Ibuzatrelvir can be used to inhibit COVID-19 <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	SARS-CoV-2 3CL protease, COVID-19 <sup>[1]</sup>

### REFERENCES

[1]. Owen, et al. Preparation of peptidomimetic nitriles as SARS-CoV-2 3CL protease inhibitors and methods for the treatment of COVID-19. World Intellectual Property Organization, WO2021250648 A1. 2021-12-16.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA